Annual General Meeting on April 29, 2020 Procedures for obtaining preparatory documents for the General Meeting

GenSight Biologics Announces the Filing of its 2019 Universal Registration Document

GenSight Biologics Provides Update on Operations in the Context of COVID-19

GenSight Biologics Reports Full Year 2019 Financial Results and provides an Outlook on 2020

2020 Cell & Gene Meeting on the Mediterranean, Barcelona, Spain – cancelled

Bio Europe Spring, Paris, France

GenSight Biologics Reports its Cash Position as of December 31, 2019 and Provides Operational Update

GenSight Biologics Announces its 2020 Financial Calendar

GenSight Biologics Announces the Filing of its 2018 Universal Registration Document

GenSight Biologics obtains €15 million in financing through a bond issuance from Kreos Capital and a reserved capital increase from Sofinnova and 3SBio